Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NNVC – NanoViricides Inc

NNVC — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

3.84

Margin Of Safety %

Put/Call OI Ratio

0.03

EPS Next Q Diff

0.03

EPS Last/This Y

0.28

EPS This/Next Y

Price

1.09

Target Price

6

Analyst Recom

1

Performance Q

-16.92

Upside

-677.8%

Beta

1.37

Ticker: NNVC




16 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09NNVC0.95230.020.003853
2026-03-10NNVC0.97190.020.003854
2026-03-11NNVC1.140.020.003856
2026-03-12NNVC1.1580.020.003937
2026-03-13NNVC1.160.020.003937
2026-03-17NNVC1.140.020.004347
2026-03-18NNVC1.1450.020.004344
2026-03-20NNVC1.040.020.144386
2026-03-25NNVC0.95250.030.003070
2026-03-26NNVC0.96890.030.003073
2026-03-27NNVC0.90620.030.003075
2026-03-30NNVC0.87150.030.003085
2026-03-31NNVC0.92730.030.003098
2026-04-01NNVC0.9540.030.003103
2026-04-06NNVC1.010.030.003127
2026-04-07NNVC1.080.030.003134
DateSymbolLatestP/C OIP/C VolTotal OI
16 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09NNVC1.01- - -0.35
2026-03-10NNVC0.96- - -0.35
2026-03-11NNVC1.14- - -0.35
2026-03-12NNVC1.16- - -0.35
2026-03-13NNVC1.17- - -0.35
2026-03-17NNVC1.13- - -0.35
2026-03-18NNVC1.14- - -0.35
2026-03-19NNVC1.04- - -0.35
2026-03-20NNVC1.02- - -0.35
2026-03-23NNVC0.99- - -0.35
2026-03-24NNVC0.95- - -0.35
2026-03-25NNVC0.95- - -0.35
2026-03-26NNVC0.95- - -0.35
2026-03-27NNVC0.91- - -0.35
2026-03-30NNVC0.88- - -0.35
2026-03-31NNVC0.93- - -0.35
2026-04-01NNVC0.95- - -0.35
2026-04-02NNVC0.93- - -0.35
2026-04-06NNVC1.00- - -0.35
2026-04-07NNVC1.09- - -0.35
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09NNVC0.001.624.02
2026-03-10NNVC0.001.624.02
2026-03-11NNVC0.001.624.59
2026-03-12NNVC0.001.624.59
2026-03-13NNVC0.001.624.59
2026-03-18NNVC0.001.564.59
2026-03-19NNVC0.001.564.59
2026-03-20NNVC0.001.564.59
2026-03-23NNVC0.001.564.59
2026-03-24NNVC0.001.564.59
2026-03-25NNVC0.001.563.84
2026-03-26NNVC0.001.563.84
2026-03-27NNVC0.001.563.84
2026-03-30NNVC0.001.563.84
2026-03-31NNVC0.001.563.84
2026-04-01NNVC0.001.563.84
2026-04-02NNVC0.001.563.84
2026-04-06NNVC0.001.563.84
2026-04-07NNVC0.001.563.84
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.11

Avg. EPS Est. Current Quarter

-0.08

Avg. EPS Est. Next Quarter

-0.08

Insider Transactions

Institutional Transactions

1.56

Beta

1.37

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

8

Growth Score

18

Sentiment Score

43

Actual DrawDown %

86.2

Max Drawdown 5-Year %

-86.3

Target Price

6

P/E

Forward P/E

PEG

P/S

P/B

2.11

P/Free Cash Flow

EPS

-0.48

Average EPS Est. Cur. Y​

-0.35

EPS Next Y. (Est.)

-0.35

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.66

Return on Equity vs Sector %

-102.6

Return on Equity vs Industry %

-86.1

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.35

EBIT Estimation

NNVC Healthcare
$1.08
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
6/20
Pullback
4/25
Volume
3/15
Valuation
12/20
TP/AR
2/10
Options
7/10
RSI
57.5
Range 1M
53.8%
Sup Dist
10.5%
🚀
Momentum Growth
Ride accelerating trends
N/A
29 /100
WEAK
Momentum
3/25
Growth
10/30
Estimates
1/20
Inst/Vol
7/15
Options
8/10
EPS Yr
0%
EPS NY
0%
52W%
17%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +455.6% upside
Quality
2/30
Valuation
16/30
Growth
6/25
Stability
7/10
LT Trend
1/5
Upside
+455.6%
Quality
8
NanoViricides, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 7
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
NNVC

Latest News

Caricamento notizie per NNVC
stock quote shares NNVC – NanoViricides Inc Stock Price stock today
news today NNVC – NanoViricides Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NNVC – NanoViricides Inc yahoo finance google finance
stock history NNVC – NanoViricides Inc invest stock market
stock prices NNVC premarket after hours
ticker NNVC fair value insiders trading